Journals / Turkish Journal of Gastroenterology / 2013 / Cilt: 24 - Sayı: 2

Gastrointestinal kanamalı hastalarda düşük doz enterik kaplı aspirinin devamlı kullanılması ve gastrointestinal hasar arasındaki ilişki

Relationship between continuous use of low-dose enteric-coated aspirin and gastrointestinal injuries in patients with gastrointestinal hemorrhage

Pages
93–98
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall prevalence of peptic ulcer disease in those with confirmed Helicobacter pylori in- fection was significantly higher than in non-infected ones (p<0.001).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: Gastrointestinal disorders are important side effects of aspirin therapy, even if the low-dose enteric-coated form is administered.
📊
Key Findings & Data:Materials and Methods: This prospective study was conducted among 633 consecutive patients with gastrointestinal hemorrhage who admitted to our tertiary referral hospital for endoscopy assessment.
💡
Conclusion & Impact:Overall prevalence of peptic ulcer disease in those with confirmed Helicobacter pylori in- fection was significantly higher than in non-infected ones (p<0.001).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aims: Gastrointestinal disorders are important side effects of aspirin therapy, even if the low-dose enteric-coated form is administered. The aim of the current study was to present the upper and lower endoscopic features of patients with gastrointes- tinal hemorrhage using low-dose enteric-coated aspirin. Materials and Methods: This prospective study was conducted among 633 consecutive patients with gastrointestinal hemorrhage who admitted to our tertiary referral hospital for endoscopy assessment. Patients were divided into two groups as low-dose aspirin users (n=168) and non-aspirin users (n=495). Aspirin users included tho- se who were taking 80-100 mg of enteric-coated aspirin per day. Results: Ulcer lesions were found in 78 patients in the aspirin user group and in 113 patients in the control group. Prevalence of duodenal ulcer was statistically similar between the two groups; ho- wever, gastric ulcer was seen more in the aspirin-user group. The use of low-dose aspirin could strongly predict gastric ulcers in the patients examined by endoscopy (p<0.001). Overall prevalence of peptic ulcer disease in those with confirmed Helicobacter pylori in- fection was significantly higher than in non-infected ones (p<0.001). The presence of this infection was strongly associated with pep- tic ulcer disease in the aspirin-user group (p<0.001). Multivariable analysis also demonstrated that the use of aspirin had a main triggering effect on short-term mortality following gastrointestinal endoscopy (p=0.003). Conclusions: Low-dose enteric-coated as- pirin causes significant gastric endoscopic lesions and even predicts mortality due to progression of gastrointestinal disorders.

Özet

Amaç: Gastrointestinal bozukluklar, düşük doz enterik-kaplı formu kullanılsa bile aspirin tedavisinin hayati yan etkilerindendir. Bu çalışmanın amacı, gastrointestinal kanamalı hastalarda düşük doz enterik-kaplı aspirine bağlı üst ve alt endoskopik bulgula- rı sunmaktır. Gereç ve Yöntem: Bu prospektif çalışma, üçüncü basamak referans merkezimize endoskopik değerlendirme için gas- trointestinal kanama ile başvuran ardışık 633 hastada yapılmıştır. Hastalar iki gruba ayrılmıştır; düşük doz aspirin kullananlar (n=168) ve aspirin kullanmayanlar (n=495). Aspirin kullananlar günde 80-100 mg enterik-kaplı aspirin alanlardan oluşmaktay- dı. Bulgular: Ülser lezyonları aspirin kullanan grupta 78 hastada ve kontrol grubunda 113 hastada bulundu. Duodenal ülser pre- valansı iki grup arasında istatistiksel açıdan benzerdi; ancak gastrik ülser aspirin kullanan grupta daha fazla görüldü. Düşük doz aspirin kullanımı endoskopi yapılan hastalarda gastrik ülser riskini artırıyordu (p < 0.001). Konfirme edilmiş Helikobakter pilori infeksiyonu olan hastalarda, olmayanlara göre genel peptik ülser prevalansı anlamlı şekilde yüksekti (p < 0.001). Bu infeksiyonun varlığı aspirin kullanan grupta peptik ülser hastalığı ile kuvvetli şekilde ilişkili bulundu (p < 0.001). Çok değişkenli analizde ay- rıca aspirinin gastrointestinal endoskopi sonrası kısa dönem mortaliteyi belirleyen ana tetikleyici etmen olduğu görüldü (p = 0.003). Sonuç: Düşük doz enterik-kaplı aspirin, belirgin gastrik endoskopik lezyonların oluşmasına ve gastrointestinal hastalığın ilerle- mesi sonucunda mortalitenin artmasına neden olmaktadır.

🔖

Cite This Article

MOUSAVI, M., SALEHIMARZIJARANI, B., DADVAR, Z., JALALY, N. Y., VALIZADEH, N., SOTOUDEH, H., ZALI, M. (2013). Gastrointestinal kanamalı hastalarda düşük doz enterik kaplı aspirinin devamlı kullanılması ve gastrointestinal hasar arasındaki ilişki. Turkish Journal of Gastroenterology, Cilt: 24 - Sayı: 2, 93–98. https://ajindex.com/articles/409572

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Bochner F, Siebert DM, Rodgers SE, et al. Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacy- clin production. Thromb Haemost 1989; 61: 211-6
  2. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-18
  3. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin- associated major upper-gastrointestinal bleeding with en- teric-coated or buffered product. Lancet 1996; 348: 1413-6
  4. Nema H, Kato M, Katsurada T, et al. Endoscopic survey of low-dose aspirin-induced gastroduodenal mucosal injuries in patients with ischemic heart disease. J Gastroenterol Hepatol 2008; 23 (Suppl 2): S234-6
  5. Venerito M, Treiber G, Wex T, et al. Effects of low-dose as- pirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E2 do not depend on Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23: 1225- 33
  6. Rodriguez LAG, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non- steroidal anti-inflammatory drugs. Lancet 1994; 343: 769–72
  7. Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspi- rin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002; 16: 1945-53
  8. Rostom A, Moayyedi P, Hunt R. Canadian consensus gu- idelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009; 29: 481-96
  9. Shiotani A, Sakakibara T, Yamanaka Y, et al. Upper gas- trointestinal ulcer in Japanese patients taking low-dose as- pirin. J Gastroenterol 2009; 44: 126-31
  10. Nema H, Kato M, Katsurada T, et al. Investigation of gas- tric and duodenal mucosal defects caused by low-dose aspi- rin in patients with ischemic heart disease. J Clin Gastro- enterol 2009; 43: 130-2
  11. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin- associated major upper-gastrointestinal bleeding with en- teric-coated or buffered product. Lancet 1996; 348: 1413-6
  12. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other non-steroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834-9
  13. Capet C, Czernichow P, Dupas J, et al. Upper gastrointes- tinal bleeding in patients treated by low-dose aspirin. Gas- troenterol Clin Biol 2001; 25: 233-8
  14. Laine L. Review article: gastrointestinal bleeding w